Despite growing interest in outcomes-based contracting as a way to combat high drug prices, former Pfizer Global Research and Development president John LaMattina says the alternative payment model is not the ultimate solution.
LaMattina in an article published on Forbes pointed to Amgen’s outcomes-based agreement for Repatha. He writes that despite the drugmaker offering a refund in the event of the patient having a heart attack while on the drug, certain parameters complicated the benefits.
They key issue, LaMattina writes, is how drugmakers set list prices.
“Clearly outcomes-based pricing is not a panacea for reducing drug costs,” he writes. “Competition and continued pressure from payers will likely play a more important role … .”
To read the full article on Forbes, click here.
